{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:48:32Z","timestamp":1785682112107,"version":"3.56.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.34633","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T16:00:51Z","timestamp":1611676851000},"page":"e2034633","source":"Crossref","is-referenced-by-count":43,"title":["Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Ulka N.","family":"Vaishampayan","sequence":"first","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance K.","family":"Heilbrun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Paul","family":"Monk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Tejwani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryn","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Jasti","sequence":"additional","affiliation":[{"name":"John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberlee","family":"Dobson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Dickow","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louie","family":"Semaan","sequence":"additional","affiliation":[{"name":"Department of Urology, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Cher","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"},{"name":"Department of Urology, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fontana","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa","family":"Chinni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan"},{"name":"Department of Urology, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"issue":"2","key":"zoi201051r1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","article-title":"Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.","volume":"117","author":"Schalken","year":"2016","journal-title":"BJU Int"},{"issue":"2","key":"zoi201051r2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi201051r3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201051r4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201051r5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi201051r6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi201051r7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"zoi201051r8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi201051r9","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system.","volume":"126","author":"Riviere","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"zoi201051r10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.urology.2004.05.024","article-title":"Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.","volume":"64","author":"Thatai","year":"2004","journal-title":"Urology"},{"issue":"14","key":"zoi201051r11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer.","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"28","key":"zoi201051r12","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials.","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi201051r13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis.","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol Cancer"},{"issue":"11","key":"zoi201051r14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/1541-7786.MCR-12-0705","article-title":"Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.","volume":"11","author":"Singareddy","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"11","key":"zoi201051r15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi201051r16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.2019.37.7_suppl.212","article-title":"Overall survival by race in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.","volume":"37","author":"McNamara","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"zoi201051r17","article-title":"Abi-Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).","volume":"36","author":"George","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi201051r18","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1200\/JCO.2019.37.15_suppl.5035","article-title":"Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): final PROCEED analysis.","volume":"37","author":"Sartor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5748","key":"zoi201051r19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"1","key":"zoi201051r20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1186\/s12885-019-6185-0","article-title":"TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.","volume":"19","author":"Semaan","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"zoi201051r21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/1078-0432.CCR-14-2352","article-title":"ERG\/AKR1C3\/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells.","volume":"21","author":"Powell","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2775631\/vaishampayan_2021_oi_201051_1613755588.50004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T17:26:54Z","timestamp":1614274014000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2775631"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.34633","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]}}}